Effectiveness of CITicoline (TRAUSAN) in preventing cognitive decline After DELirium in older adults with proximal hip fracture – The CITADEL randomized controlled trial

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522306-21-00

Acronym

CITADEL

Enrollment

122

Registered

2025-10-13

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive profiles

Brief summary

The Montreal Cognitive Assessment (MoCA) performed before discharge and at 6 months post-randomization will allow to assess the primary objective.

Detailed description

Montreal Cognitive Assessment (MoCA) performed before discharge and at 3 and 6months post-randomization, Short Physical Performance Battery (SPPB), performed at 3 and 6months post-randomization, Rates of adverse events (quantity/seriousness) during the 6-months follow-up after randomization

Interventions

DRUGTRAUSAN 1000 mg soluzione orale

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The Montreal Cognitive Assessment (MoCA) performed before discharge and at 6 months post-randomization will allow to assess the primary objective.	—

Secondary

Measure	Time frame
Montreal Cognitive Assessment (MoCA) performed before discharge and at 3 and 6months post-randomization, Short Physical Performance Battery (SPPB), performed at 3 and 6months post-randomization, Rates of adverse events (quantity/seriousness) during the 6-months follow-up after randomization	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026